First patient treated with TRANBERG Thermal Therapy System in nationwide French study evaluating MRI together with biopsies to detect residual prostate cancer after focal therapy
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announced its participation in a national French study together with Urolib (urological team of the Medical Center Chateau Galland (MCCG)) in Besançon, France, and that the first patient was safely treated with CLS TRANBERG[®] Thermal Therapy system for laser ablation of prostate cancer.The multicenter study, named the IRMPROFT Study, aims to investigate the “Performance of Prostate MRI and targeted biopsy to detect residual Prostate cancer following focal therapy”. Various focal therapy technologies are